Key facts
- SK Biopharmaceuticals (KRX: 326030) is a other based in Seongnam, Gyeonggi.
About SK Biopharmaceuticals (KRX: 326030)
SK Biopharmaceuticals is a corporation based in Seongnam-si, South Korea. Established in 1993, it develops drugs for central nervous system disorders and brain tumors. The company operates a BioScience Research Institute in Pangyo Techno Valley, Gyeonggi Province. Its drug pipeline includes Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741. The assets are managed by the executive team.
Free account
See more of the book
- ·Watchlist + alerts for SK Biopharmaceuticals (KRX: 326030)'s activity
Create free account
No card required
Portfolio
Portfolio — not yet on record
No portfolio companies for SK Biopharmaceuticals (KRX: 326030) are on record yet. Positions surface from round participations, filings, and coverage.
Pro members can request priority coverage with a 48-hour turnaround.